STOCK TITAN

Altamira Therapeutics Ltd - CYTO STOCK NEWS

Welcome to our dedicated news page for Altamira Therapeutics (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Altamira Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Altamira Therapeutics's position in the market.

Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) has completed a partial spin-off of Bentrio® to focus on RNA delivery activities. The company retains 49% in Altamira Medica AG and secures 25% of future licensing revenue. Altamira regained compliance with the minimum stockholders' equity requirement set by Nasdaq after boosting its equity position through a public offering of common shares, partial amortization of convertible debt, and the partial spin-off of Bentrio® activities. The spin-off involved the transfer of a 51% stake in Altamira Medica AG, with Altamira receiving a cash consideration of CHF 2,040,000. Nasdaq will continue to monitor the company's compliance with the stockholders' equity requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
180.43%
Tags
none
-
Rhea-AI Summary
Altamira Therapeutics Ltd. (CYTO) Initiates Strategic Repositioning to Focus on Core RNA Delivery Technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
180%
Tags
none
-
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq:CYTO) receives 'Intention to Grant' notice from European Patent Office for its patent application titled 'Intranasal Composition Comprising Betahistine', providing key intellectual property protection for the Company's intranasal betahistine program (AM-125) in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.83%
Tags
none
Rhea-AI Summary
Altamira Therapeutics announces positive efficacy data from NASAR clinical trial for Bentrio nasal spray in treatment of seasonal allergic rhinitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.72%
Tags
-
Rhea-AI Summary
Altamira Therapeutics reports 1H 2023 financial results and business update, achieving milestones in research collaborations and clinical development programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
-
Rhea-AI Summary
Altamira Therapeutics to host First Half 2023 Financial Results and Business Update Call on September 12th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences earnings
Rhea-AI Summary
Altamira Therapeutics to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
Rhea-AI Summary
Altamira Therapeutics has published detailed results from its clinical trial with Bentrio nasal spray in house dust mite allergic rhinitis. The trial showed statistically significant alleviation of nasal symptoms, with Bentrio reducing the increase in mean Total Nasal Symptom Score during allergen exposure by 1.1 points. The study also found that a single application of Bentrio provides ample protection and has a lasting protective effect for several hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.79%
Tags
Altamira Therapeutics Ltd

Nasdaq:CYTO

CYTO Rankings

CYTO Stock Data

4.10M
2.22M
0.89%
0.34%
24.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Bermuda
Hamilton

About CYTO

altamira therapeutics (former auris medical) is dedicated to developing therapeutics that address important unmet medical needs. the company is currently active in three areas: • the development of rna therapeutics for extrahepatic therapeutic targets (oligophore™ / semaphore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (bentrio™; commercial) or the treatment of vertigo (am-125; phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (keyzilen® and sonsuvi®, phase 3). the company was founded in 2003, under the name auris medical, and is headquartered in hamilton, bermuda with its main operations in basel, switzerland. the shares of altamira therapeutics ltd. trade on the nasdaq capital market under the symbol “cyto.”